Navigation Links
Genmab Announces HuMax-CD32b Pre-Clinical Program
Date:1/4/2008

eams have created and developed an extensive pipeline of products for potential treatment of a variety of diseases including cancer and autoimmune disorders. As Genmab advances towards a commercial future, we remain committed to our primary goal of improving the lives of patients who are in urgent need of new treatment options. For more information on Genmab's products and technology, visit http://www.genmab.com.

This press release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law.

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R); HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM); HuMax-CD32b(TM) and UniBody(R) are all trademarks of Genmab A/S
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Roche Files IND for Second Genmab Antibody
2. Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma
3. Genmab Announces Details of Planned Ofatumumab Phase II Study in Multiple Sclerosis
4. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
5. Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study
6. Genmab Announces Results for the First Nine Months of 2007
7. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
8. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
9. Genmab A/S - Company Announcement
10. Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study
11. Genmab Announces Asset Exchange Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... , June 30, 2015  The Dr. Samadi Prostate ... is now offering a full suite of new genetic testing ... a biopsy, for diagnosing prostate cancer. ... of genetic tests for assessing the risk and optimizing the ... "We,re very excited to now offer these revolutionary genetic ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... launched “Cannavoices,” an unprecedented digital video and broadcast initiative. Produced by filmmakers, the ... dynamic collection of legal medical cannabis stories ever assembled. , Cannavoices profiles ...
(Date:6/29/2015)... , ... June 29, 2015 , ... ... B2. Under the terms of the agreement, MediVet will acquire the rights to ... (UCMSCs). MB-007 is currently in pre-clinical development as a potential next-generation treatment for ...
(Date:6/29/2015)... 29, 2015  AACC, a global scientific and ... laboratory medicine, is pleased to announce that the ... , has increased to 7.9 in the 2014 ... Clinical Chemistry in the top 3% ... influence of the research it publishes on laboratory ...
Breaking Biology Technology:New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 2New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 3New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 4New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 5Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 2Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 3MediVet Biologics Acquires Exclusive Patent License from Kansas State University 2MediVet Biologics Acquires Exclusive Patent License from Kansas State University 3AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 2AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 3
... , , BOTHELL, Wash., Aug. 7 ... reported financial results for the three and six months ended June ... Morra, SCOLR Pharma,s President and CEO, said, "We continue to advance ... release ibuprofen. These potential partners have been committing resources to due ...
... EXTON, Pa., Aug. 7 Kensey Nash Corporation ... the distribution rights, along with the trademark, inventory and ... product line. Under the terms of the agreement, the ... existing OsseoFit distribution agreement. Pursuant to the agreement, following ...
... , CORAL GABLES, Fla., Aug. 7 Catalyst Pharmaceutical Partners, Inc. ... and six months ended June 30, 2009. , , ... For the quarter ended June 30, 2009, the Company reported a net loss ... loss of $2,377,440, or $0.19 per basic and diluted share for the same ...
Cached Biology Technology:SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 2SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 3SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 4SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 5SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 6SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 7SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 8Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product 2Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product 3Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 2Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 3Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 4Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 5Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 6Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 7
(Date:6/24/2015)... June 24, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced that Sharp has selected its ... authentication for its latest flagship smartphone device, the ... 200 million shipments of its fingerprint ID sensor ... strength, scalability and leadership in the biometrics market ...
(Date:6/23/2015)...   MedNet Solutions , an innovative SaaS-based ... of clinical research, is pleased to announce that ... company,s intuitive, flexible and affordable cloud-based eClinical technology ... Award by the American Business Awards (SM) ... The American Business Awards are considered the nation,s ...
(Date:6/23/2015)... , June 23, 2015  Crossmatch™, ... and authentication solutions, today announced enhanced functionality of ... authentication solution.  The enhancements build on the ... the DigitalPersona Altus platform and provide expanded ... In today,s environment of increasing ...
Breaking Biology News(10 mins):Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2
... a major food source for much of the world, rice is ... safe from disease has become, in part, the task of a ... Kansas State University. The researchers are looking at two bacterial ... which is caused by a bacterium called Xanthomonas oryzae pathovar ...
... Engineers at Oregon State University have made a major ... run a cooling system a technology that can improve ... will appear in automobiles, homes and industry. This heat-actuated ... the U.S. Army, could ultimately be applied to automobiles, factories ...
... herders are facing the challenges of adapting to climate ... for herds to find food and navigate. To help ... them with satellite-based snow maps. "Snow is of ... whether reindeer are able to access the pastures that ...
Cached Biology News:Researchers examine bacterial rice diseases, search for genetic solutions 2Breakthrough made in energy efficiency, use of waste heat 2Breakthrough made in energy efficiency, use of waste heat 3Satellite snow maps help reindeer herders adapt to a changing Arctic 2
Agarose for baculovirus plaque assays which allow optimal growth of plated insect cells....
BD BaculoGold Max-XP Insect Cell Medium 1 Liter...
Mycoplasma and virus tested...
Edited by I.H. Pawlowitzki, J.H. Edwards and E.A. Thompson (1997) • This volume covers: Linkage in dominant recessive and oligogenic disease, Model free (non-parametric) methods, Tools for gene ...
Biology Products: